Newest Research Supports New AIDS

[HEENTORRY]

The new study, published in the Oct. 2 issue of the New England Journal of Medicine, followed 1,049 HIV patients who were resistant to three classes of HIV drugs. Some patients received doses of maraviroc, while others received a placebo. The study was funded by Pfizer Inc., the maker of the drug.Between 42 percent and 47 percent of the patients taking maraviroc reached reduced levels of the AIDS virus in their bodies, compared to 17 percent of the placebo group."There were no apparent side effects or toxicity differences in patients that got maraviroc vs. placebo," Gulick said. "It looked safe and generally well-tolerated over 48 weeks." somas cafe phoenix adalat nadolol interaction breast augmentation for man tramadol drug tets alcohol and plavix elavil and seizures lexapro patent teva alabama clas what is lotrisone cream used for where can you buy hoodia 911